• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病神经病理生理机制中的恶性循环。

Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease.

作者信息

Standridge John B

机构信息

Department of Family Medicine, University of Tennessee Health Science Center College of Medicine, Chattanooga, Tennessee 37403, USA.

出版信息

Curr Alzheimer Res. 2006 Apr;3(2):95-108. doi: 10.2174/156720506776383068.

DOI:10.2174/156720506776383068
PMID:16611010
Abstract

Rigorous scientific research has identified multiple interactive mechanisms that parallel and are likely causative of the development of Alzheimer's disease (AD). Causative mechanisms include genomics, the creation of amyloid beta (Abeta), factors inhibiting the Abeta removal process, the transformation of Abeta to its toxic forms (various forms of Abeta aggregation), and lastly the oxidative, inflammatory, and other effects of toxic Abeta. Fibrillar beta-amyloid peptide, a major component of senile plaques in AD brain, is known to induce microglial-mediated neurotoxicity under certain conditions, but some recent studies support the notion that Abeta oligomers are the primary neurotoxins. Abeta-42 oligomers that are soluble and highly neurotoxic, referred to as Abeta-derived diffusible ligands (ADDLs), assemble under conditions that block fibril formation. These oligomers bind to dendrite surfaces in small clusters with ligand-like specificity and are capable of destroying hippocampal neurons at nanomolar concentrations. Evidence is presented that AD is triggered by these soluble, neurotoxic assemblies of Abeta rather than the late stage pathology landmarks of amyloid plaques and tangles. The premise is that AD symptoms stem from aberrant nerve cell signaling and synaptic failure rather than nerve cell death, which nevertheless follows and exacerbates the initial pathologies of AD. The defective clearance of amyloid leads to amyloid angiopathy that in turn perpetuates hypoperfusion that affects formation as well as absorption of CSF thereby altering clearance of amyloid and promoting vascular and parenchymal deposition[1]. Hypoperfusion, the defective clearance of amyloid, and resultant increase in amyloid deposition thus represent a vicious cycle. Chronic vascular hypoperfusion-induced mitochondrial failure results in oxidative damage, which drives caspase 3-mediated Abeta peptide secretion and enhances amyloidogenic APP processing. Intracellular Abeta accumulation in turn promotes a significant oxidative and inflammatory mechanism that generates a vicious cycle of Abeta generation and oxidation, each accelerating the other. Abeta activates astrocytes that add to the oxidative imbalance, upregulate the expression of APP via TGF-beta, and are capable of expressing BACE1. Each of these 3 actions accelerates the larger cycle of cholinergic neuron destruction. As oxidative stress induces lesions of cholinergic nuclei producing a reduction in cholinergic neurotransmission, a subsequent increase in cortical APP involving PKCepsilon leads to accelerated amyloidogenic APP metabolism. The linkage of cholinergic activation and APP metabolism completes an additional feedback loop wherein the damage wrought by Abeta accelerates further Abeta production. A comprehensive vision of the neuropathophysiologic mechanisms that result in AD reveals several vicious cycles within a larger vicious cycle, that is to say, a number of interactive systems that each, once set in motion, amplify their own processes, thus accelerating the development of AD.

摘要

严谨的科学研究已确定了多种相互作用机制,这些机制与阿尔茨海默病(AD)的发展并行且可能是其病因。致病机制包括基因组学、β-淀粉样蛋白(Aβ)的产生、抑制Aβ清除过程的因素、Aβ向其毒性形式的转化(Aβ的各种聚集形式),以及最后有毒Aβ的氧化、炎症和其他作用。纤维状β-淀粉样肽是AD大脑中老年斑的主要成分,已知在某些条件下会诱导小胶质细胞介导的神经毒性,但最近的一些研究支持Aβ寡聚体是主要神经毒素的观点。可溶性且具有高度神经毒性的Aβ-42寡聚体,称为Aβ衍生的可扩散配体(ADDLs),在阻止纤维形成的条件下组装。这些寡聚体以类似配体的特异性以小簇形式结合到树突表面,并且能够在纳摩尔浓度下破坏海马神经元。有证据表明,AD是由这些可溶性、神经毒性的Aβ组装体引发的,而不是淀粉样斑块和缠结的晚期病理标志。前提是AD症状源于异常的神经细胞信号传导和突触功能障碍,而不是神经细胞死亡,尽管神经细胞死亡会随之发生并加剧AD的初始病理过程。淀粉样蛋白清除缺陷导致淀粉样血管病,进而使灌注不足持续存在,这会影响脑脊液的形成和吸收,从而改变淀粉样蛋白的清除并促进血管和实质沉积[1]。灌注不足、淀粉样蛋白清除缺陷以及由此导致的淀粉样蛋白沉积增加因此代表了一个恶性循环。慢性血管灌注不足诱导的线粒体功能衰竭导致氧化损伤,这驱动半胱天冬酶3介导的Aβ肽分泌并增强淀粉样前体蛋白(APP)的加工。细胞内Aβ积累反过来促进显著的氧化和炎症机制,产生Aβ生成和氧化的恶性循环,二者相互加速。Aβ激活星形胶质细胞,这会加剧氧化失衡,通过转化生长因子-β上调APP的表达,并能够表达β-分泌酶1(BACE1)。这三种作用中的每一种都会加速胆碱能神经元破坏的更大循环。由于氧化应激诱导胆碱能核损伤,导致胆碱能神经传递减少,随后涉及蛋白激酶Cε(PKCε)的皮质APP增加会导致淀粉样前体蛋白代谢加速。胆碱能激活与APP代谢的联系完成了另一个反馈回路,其中Aβ造成的损伤会加速更多Aβ的产生。对导致AD的神经病理生理机制的全面认识揭示了一个更大恶性循环中的几个恶性循环,也就是说,一些相互作用的系统,一旦启动,每个系统都会放大自身过程,从而加速AD的发展。

相似文献

1
Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease.阿尔茨海默病神经病理生理机制中的恶性循环。
Curr Alzheimer Res. 2006 Apr;3(2):95-108. doi: 10.2174/156720506776383068.
2
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
3
β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.β-淀粉样蛋白、胆碱能传递和脑血管系统——阿尔茨海默病小鼠模型的发育研究。
Curr Pharm Des. 2013;19(38):6749-65. doi: 10.2174/13816128113199990711.
4
[Alzheimer disease: cellular and molecular aspects].[阿尔茨海默病:细胞与分子层面]
Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1.
5
Beta-amyloid, neuronal death and Alzheimer's disease.β-淀粉样蛋白、神经元死亡与阿尔茨海默病
Curr Mol Med. 2001 Dec;1(6):733-7. doi: 10.2174/1566524013363177.
6
[Involvement of beta-amyloid in the etiology of Alzheimer's disease].β-淀粉样蛋白在阿尔茨海默病病因学中的作用
Brain Nerve. 2010 Jul;62(7):691-9.
7
Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.在阿尔茨海默病小鼠模型中通过β-分泌酶1逆向转运调控突触淀粉样β蛋白的生成
J Neurosci. 2017 Mar 8;37(10):2639-2655. doi: 10.1523/JNEUROSCI.2851-16.2017. Epub 2017 Feb 3.
8
Alzheimer's disease pathogenesis and therapeutic interventions.阿尔茨海默病的发病机制与治疗干预措施。
J Clin Neurosci. 2004 Jun;11(5):456-67. doi: 10.1016/j.jocn.2003.12.007.
9
Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A in a spatial-specific manner.寡聚淀粉样β以空间特异性方式诱导脑胞质和钙非依赖性磷脂酶 A 的 MAPK 介导的激活。
Acta Neuropathol Commun. 2017 Jul 27;5(1):56. doi: 10.1186/s40478-017-0460-6.
10
Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.解析具有生物活性的人源 AD 脑可溶性 Aβ 的突触功能障碍,为阿尔茨海默病提供新的治疗途径。
Acta Neuropathol Commun. 2018 Nov 8;6(1):121. doi: 10.1186/s40478-018-0626-x.

引用本文的文献

1
Role of insulin-like growth factor-2 in Alzheimer's disease induced memory impairment and underlying mechanisms.胰岛素样生长因子-2在阿尔茨海默病所致记忆障碍中的作用及潜在机制
Front Cell Neurosci. 2025 Jan 3;18:1520253. doi: 10.3389/fncel.2024.1520253. eCollection 2024.
2
Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer's disease.胰岛素样生长因子-2 是治疗和预防阿尔茨海默病的有前途的候选药物。
CNS Neurosci Ther. 2023 Jun;29(6):1449-1469. doi: 10.1111/cns.14160. Epub 2023 Mar 27.
3
Neuroprotective Effect of Artichoke-Based Nanoformulation in Sporadic Alzheimer's Disease Mouse Model: Focus on Antioxidant, Anti-Inflammatory, and Amyloidogenic Pathways.
基于朝鲜蓟的纳米制剂在散发性阿尔茨海默病小鼠模型中的神经保护作用:聚焦于抗氧化、抗炎和淀粉样蛋白生成途径
Pharmaceuticals (Basel). 2022 Sep 28;15(10):1202. doi: 10.3390/ph15101202.
4
Therapeutic Potential of Different Natural Products for the Treatment of Alzheimer's Disease.不同天然产物治疗阿尔茨海默病的治疗潜力
Oxid Med Cell Longev. 2022 Jul 22;2022:6873874. doi: 10.1155/2022/6873874. eCollection 2022.
5
Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from .用于抗阿尔茨海默病的中药:来自……的小檗碱和吴茱萸碱
Chin Med. 2020 Aug 5;15:82. doi: 10.1186/s13020-020-00359-1. eCollection 2020.
6
The emergence of Ephexin5 as a therapeutic target in Alzheimer's disease.埃菲辛5(Ephexin5)作为阿尔茨海默病治疗靶点的出现。
Expert Opin Ther Targets. 2019 Apr;23(4):263-265. doi: 10.1080/14728222.2019.1586884. Epub 2019 Mar 5.
7
Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A in a spatial-specific manner.寡聚淀粉样β以空间特异性方式诱导脑胞质和钙非依赖性磷脂酶 A 的 MAPK 介导的激活。
Acta Neuropathol Commun. 2017 Jul 27;5(1):56. doi: 10.1186/s40478-017-0460-6.
8
Deposition of BACE-1 Protein in the Brains of APP/PS1 Double Transgenic Mice.β-分泌酶1(BACE-1)蛋白在APP/PS1双转基因小鼠大脑中的沉积。
Biomed Res Int. 2016;2016:8380618. doi: 10.1155/2016/8380618. Epub 2016 May 18.
9
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics.针对适当的淀粉样β神经元毒素:阿尔茨海默病免疫疗法的前进道路。
Alzheimers Res Ther. 2014 Jul 9;6(4):42. doi: 10.1186/alzrt272. eCollection 2014.
10
Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.多靶点导向配体及其他治疗策略在阿尔茨海默病治疗中的探索。
Curr Neuropharmacol. 2014 Jan;12(1):2-36. doi: 10.2174/1570159X113116660047.